WEGO
Shandong Weigao Group Medical Polymer Products Co. and its subsidiaries are principally engaged in the research and development
Shandong Weigao Group Medical Polymer Products Co. and its subsidiaries are principally engaged in the research and development, manufacture and sale of disposable medical devices. We provide different kinds of products, including: i) consumables (infusion sets, syringes, medical needle products, blood bags, pre-filled syringes, blood collection products and other consumables used); ii) bone materials and iii) blood purification consumables and equipment. The Company is the industrialization base of the achievements of the National High Technology Research and Development (863) Program of China, a national high-tech enterprise and a national enterprise technology center. The main production base of the Group is located in Weihai City, Shandong Province, the PRC.
F-star to be acquired by China biopharmaceutical with USD 161million
"Delisting warning" of Whitson pharmaceuticals on the New York Stock Exchange
BeiGene: a Vast Opportunity Lies Ahead – But We Remain Cautious
BeiGene, a leader in China's novel pharmaceutical industry, recently received approval in Kuwait, Bahrain, and Qatar for its medication BRUKINSA (zanubrutinib). Previous contracts with major biopharma have produced substantial licensing income, but they did not lessen BeiGene's financial burden.
Jun 24, 2022 12:13 PM
East China medicine "liraglutide" goes to sea
Research
Technology, Healthcare, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Nearly half of the equity of two subsidiaries of Tongrentang was transferred to Tongrentang medical care
Baiyunshan: suspension of the spin off of Guangzhou Pharmaceutical for overseas listing
Germany Merck "cetuximab" new indications for head and neck squamous cell carcinoma approved in China
Yanye new crown drug 3CL protein inhibitor has been suspended approval
NK Celltech Receives a Series A Round of Funding Worth More Than CNY 100 Million
NK Celltech recently received a Series A round of funding totaling more than CNY 100 million. Huagai Capital led this round of funding, which was followed by CASVC, Unifortune, 呈益资本, Sirius Capital, and QJ Capital.
Jul 01, 2022 03:58 PM
Sanofi Greater China will be headed by Shi Wang, and Henting he will become the global head of the digital business unit
Acadia Alzheimer's drug SNDA application rejected by FDA advisory committee
Huashen Zhiyao completed nearly 500million yuan of a-round financing and went deep into AI new drug development
Huamei Haolian, a health management service enterprise, completed round a+ financing, and Jinshajiang venture capital led the investment
Mojia biology announced the completion of round B financing
Ruiyuan Zhao Feng position announced in the second quarter, Xiaomi group is still the largest position stocks